Skip Navigation LinksHome > May 2014 - Volume 24 - Issue 4 > Phase II Trial on Cisplatin-Adriamycin-Paclitaxel Combinatio...
International Journal of Gynecological Cancer:
doi: 10.1097/IGC.0000000000000115
Cervical Cancer

Phase II Trial on Cisplatin-Adriamycin-Paclitaxel Combination as Neoadjuvant Chemotherapy for Locally Advanced Cervical Adenocarcinoma

Lorusso, Domenica MD; Ramondino, Stefano MD; Mancini, Maria MD; Zanaboni, Flavia MD; Ditto, Antonino MD; Raspagliesi, Francesco PhD

Collapse Box

Abstract

Objective

Neoadjuvant chemotherapy (NACT) followed by surgery is a different therapeutic approach to locally advanced cervical adenocarcinoma (LACA) and seems to offer specific advantages over chemoradiation. This phase II trial was designed to evaluate the toxicity and activity of NACT with cisplatin-adriamycin-paclitaxel (TAP) in patients with LACA.

Methods

Patients with International Federation of Gynecology and Obstetrics stage IB2–IIB uterine adenocarcinoma were treated with NACT TAP for 3 cycles. After the last cycle, patients underwent radical surgery with lymph node dissection. Pathological response was classified as no residual tumor (pCR), residual disease with less than 3-mm stromal invasion (pR1), or residual disease with more than 3-mm stromal invasion (pR2).

Results

Between 2003 and 2010, 30 women were enrolled. Fourteen complete clinical responses, 10 partial responses, and 6 stabilizations of disease were registered. Three patients achieved a pCR, 6 a pR1 response, and 21 a pR2 response. At a median follow-up of 45 months, progression-free survival and overall survival were 37 and 48 months, respectively. Hematologic toxicity was the most relevant adverse effect.

Conclusions

The TAP combination seems to be feasible with an acceptable toxicity profile and a promising response rate for the treatment of LACA.

Copyright © 2014 by IGCS and ESGO

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/IJGConline

For additional oncology content, visit LWW Oncology Journals on Facebook.